242 related articles for article (PubMed ID: 34511000)
1. From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection.
Volpedo G; Huston RH; Holcomb EA; Pacheco-Fernandez T; Gannavaram S; Bhattacharya P; Nakhasi HL; Satoskar AR
Expert Rev Vaccines; 2021 Nov; 20(11):1431-1446. PubMed ID: 34511000
[TBL] [Abstract][Full Text] [Related]
2. Overcoming roadblocks in the development of vaccines for leishmaniasis.
Kaye PM; Mohan S; Mantel C; Malhame M; Revill P; Le Rutte E; Parkash V; Layton AM; Lacey CJN; Malvolti S
Expert Rev Vaccines; 2021 Nov; 20(11):1419-1430. PubMed ID: 34727814
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications.
Gannavaram S; Dey R; Avishek K; Selvapandiyan A; Salotra P; Nakhasi HL
Front Immunol; 2014; 5():241. PubMed ID: 24904589
[TBL] [Abstract][Full Text] [Related]
4. Vaccines against leishmaniasis: using controlled human infection models to accelerate development.
Parkash V; Kaye PM; Layton AM; Lacey CJ
Expert Rev Vaccines; 2021 Nov; 20(11):1407-1418. PubMed ID: 34664543
[TBL] [Abstract][Full Text] [Related]
5. Possibilities and challenges for developing a successful vaccine for leishmaniasis.
Srivastava S; Shankar P; Mishra J; Singh S
Parasit Vectors; 2016 May; 9(1):277. PubMed ID: 27175732
[TBL] [Abstract][Full Text] [Related]
6. Genetically modified live attenuated parasites as vaccines for leishmaniasis.
Selvapandiyan A; Duncan R; Debrabant A; Lee N; Sreenivas G; Salotra P; Nakhasi HL
Indian J Med Res; 2006 Mar; 123(3):455-66. PubMed ID: 16778323
[TBL] [Abstract][Full Text] [Related]
7. [Approaches and problems in vaccine development against leishmaniasis].
Allahverdiyev A; Bağirova M; Cakir Koç R; Oztel ON; Elçıçek S; Ateş SC; Karaca TD
Turkiye Parazitol Derg; 2010; 34(2):122-30. PubMed ID: 20597059
[TBL] [Abstract][Full Text] [Related]
8. The development and clinical evaluation of second-generation leishmaniasis vaccines.
Duthie MS; Raman VS; Piazza FM; Reed SG
Vaccine; 2012 Jan; 30(2):134-41. PubMed ID: 22085553
[TBL] [Abstract][Full Text] [Related]
9. Vaccine candidates against leishmania under current research.
Iborra S; Solana JC; Requena JM; Soto M
Expert Rev Vaccines; 2018 Apr; 17(4):323-334. PubMed ID: 29589966
[TBL] [Abstract][Full Text] [Related]
10. Social and Economic Burden of Human Leishmaniasis.
Okwor I; Uzonna J
Am J Trop Med Hyg; 2016 Mar; 94(3):489-93. PubMed ID: 26787156
[TBL] [Abstract][Full Text] [Related]
11. Vaccine value profile for leishmaniasis.
Kaye PM; Matlashewski G; Mohan S; Le Rutte E; Mondal D; Khamesipour A; Malvolti S
Vaccine; 2023 Nov; 41 Suppl 2():S153-S175. PubMed ID: 37951693
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic vaccines for leishmaniasis.
Khamesipour A
Expert Opin Biol Ther; 2014 Nov; 14(11):1641-9. PubMed ID: 25077737
[TBL] [Abstract][Full Text] [Related]
13. Human leishmaniasis vaccines: Use cases, target population and potential global demand.
Malvolti S; Malhame M; Mantel CF; Le Rutte EA; Kaye PM
PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009742. PubMed ID: 34547025
[TBL] [Abstract][Full Text] [Related]
14. Development of nano-carriers for
Askarizadeh A; Badiee A; Khamesipour A
Expert Opin Drug Deliv; 2020 Feb; 17(2):167-187. PubMed ID: 31914821
[No Abstract] [Full Text] [Related]
15. The Delay in the Licensing of Protozoal Vaccines: A Comparative History.
Palatnik-de-Sousa CB; Nico D
Front Immunol; 2020; 11():204. PubMed ID: 32210953
[TBL] [Abstract][Full Text] [Related]
16. Progress towards a Leishmania vaccine.
Tabbara KS
Saudi Med J; 2006 Jul; 27(7):942-50. PubMed ID: 16830009
[TBL] [Abstract][Full Text] [Related]
17. Status of vaccine research and development of vaccines for leishmaniasis.
Gillespie PM; Beaumier CM; Strych U; Hayward T; Hotez PJ; Bottazzi ME
Vaccine; 2016 Jun; 34(26):2992-2995. PubMed ID: 26973063
[TBL] [Abstract][Full Text] [Related]
18. Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates.
Mohan S; Revill P; Malvolti S; Malhame M; Sculpher M; Kaye PM
PLoS Negl Trop Dis; 2022 Jun; 16(6):e0010471. PubMed ID: 35696433
[TBL] [Abstract][Full Text] [Related]
19. Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: Protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB/c mice.
Elikaee S; Mohebali M; Rezaei S; Eslami H; Khamesipour A; Keshavarz H; Eshraghian MR
Vaccine; 2019 May; 37(24):3221-3228. PubMed ID: 31047672
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
